反应详情

Using the procedure outlined in Example 1(g) the title compound was prepared from 4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamine (53 mg, 0.24 mmol) and 8-indan-5-yl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 1(e) above, 100 mg, 0.24 mmol). The title compound was obtained as a yellow solid (70 mg, 53%). 1H NMR (400 MHz, CDCl3) δ (ppm): 9.28 (s, 1H), 8.46 (s, 1H), 7.60 (br, 1H), 7.34 (d, J=7.9 Hz, 1H), 7.21 (s, 1H), 7.16 (br, 2H), 7.12 (d, J=7.9 Hz, 1H), 6.86 (br, 2H), 4.30 (q, J=7.1 Hz, 2H), 2.99 (t, J=7.4 Hz, 2H), 2.93 (t, J=7.4 Hz, 2H), 2.64 (n, 2H), 2.47 (m, 10H), 2.34 (s, 3H), 2.16 (m, 2H), 1.32 (t, J=7.1 Hz, 3H).